Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients

Summary Allergic bronchopulmonary aspergillosis (ABPA) affects up to 15% of patients with cystic fibrosis (CF). Corticosteroids are used as first‐line therapy, but relapse and adverse effects commonly occur. Case reports have suggested the efficacy of the anti‐IgE recombinant humanized monoclonal an...

Full description

Saved in:

Bibliographic Details
Published in:	Pediatric pulmonology Vol. 52; no. 2; pp. 190 - 197
Main Authors:	Nové‐Josserand, Raphaële, Grard, Soazic, Auzou, Lila, Reix, Philippe, Murris‐Espin, Marlène, Brémont, François, Mammar, Benyebka, Mely, Laurent, Hubert, Dominique, Durieu, Isabelle, Burgel, Pierre‐Régis
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 01.02.2017
Subjects:	Adolescent Adrenal Cortex Hormones - therapeutic use Adult allergic bronchopulmonary aspergillosis (ABPA) Anti-Allergic Agents - therapeutic use Antifungal Agents - therapeutic use Aspergillosis, Allergic Bronchopulmonary - complications Aspergillosis, Allergic Bronchopulmonary - drug therapy Aspergillosis, Allergic Bronchopulmonary - immunology Aspergillus fumigatus Child corticosteroids cystic fibrosis Cystic Fibrosis - complications Drug Therapy, Combination Female Humans IgE immunoglobulin E Immunoglobulin E - immunology Male Middle Aged Omalizumab - therapeutic use Retrospective Studies Young Adult corticosteroids Aspergillus fumigatus allergic bronchopulmonary aspergillosis (ABPA) immunoglobulin E IgE cystic fibrosis
ISSN:	8755-6863, 1099-0496, 1099-0496
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!